How to Run an RFI Before Issuing a Medical Equipment RFP

A well-executed Request for Information rewrites your assumptions about the market before they harden into RFP specifications you'll later regret.

Why this matters

Picture a mid-size community hospital whose biomedical team has been told to replace 120 bedside patient monitors across three floors. The procurement officer, working under a six-month deadline, skips straight to an RFP. She specifies NIBP, SpO2, and ECG as core parameters, sets IEC 60601-1 compliance as the baseline, and limits the field to brands already on the GPO contract. When responses arrive three weeks later, they're incomparable: some vendors price per module, others per bed, one bundles central-station software while three others don't. The evaluation committee spends two months reconciling proposals never designed to sit beside each other.

That is precisely what a Request for Information prevents. An RFI is a non-binding, structured document issued to a broad vendor pool before requirements are final. Its job is not to select a supplier — it is to understand the market well enough that when you write the RFP, your specifications are realistic, complete, and produce responses that are actually comparable (S1). In medical capital equipment, where a single purchase can range from roughly $50,000 for a mid-range ultrasound to well over $1 million for advanced diagnostic imaging (specific list prices for medical capital equipment are rarely publicly verifiable), writing an RFP blind is a financial risk, not just a procedural oversight.

Healthcare procurement adds a regulatory layer that makes the RFI even more valuable. Before you commit evaluation resources to a vendor, you want to know whether their device holds current FDA 510(k) clearance, whether it meets the relevant IEC 60601-2 device-specific standard, and whether they have a service footprint in your geography. The RFI is where you establish that floor — so your RFP never lands in front of a vendor who will fail a compliance check and waste everyone's time.

The decisions that shape the outcome

How wide to cast the net

The temptation is to send the RFI only to GPO-contracted vendors or names your biomed team already knows. That saves time but defeats the point. An RFI's core value is market mapping, not pre-selection (S4). A realistic starting pool for most medical capital equipment categories runs 8 to 15 vendors. Sending to fewer than six risks missing newer entrants or niche suppliers with a technically or commercially superior offer. You will short-list to 3–5 for the actual RFP — that's the funnel working as intended.

What questions to actually ask

RFI questions should be open enough to surface information you didn't know to request, but structured enough to allow side-by-side comparison. For medical equipment, the core question areas are: company financial stability and domestic service footprint; device regulatory status (FDA device class, 510(k) number, applicable IEC 60601-2 standard); technical architecture and upgrade path; integration capability (DICOM, HL7 FHIR, or proprietary middleware); general pricing structure — per unit, per bed, subscription, or modular — without demanding a firm quote (S3); and typical implementation timeline. Asking about structure of pricing is legitimate at this stage. Asking for a binding price is not, because your final scope isn't set.

Whether to disclose a budget envelope

This is a genuine trade-off. Sharing an approximate capital budget helps vendors self-select and filters out suppliers who are structurally unable to compete at your scale. The downside is that some vendors will simply anchor their eventual proposal to the ceiling of whatever range you name. A safer approach is to share scope — number of units, care settings, integration environment — without a dollar figure, and let the pricing-structure question do the filtering (S4).

How long to give vendors to respond

Three to four weeks is the accepted response window for a complex healthcare technology RFI (S3). Shorter windows favor large vendors with dedicated bid teams and disadvantage smaller, often technically capable suppliers. Build in a single Q&A cutoff at the midpoint of the response period: collect all clarifying questions, compile answers, and circulate them simultaneously to every respondent. In public health systems this is a compliance requirement; in private settings it's simply good practice that keeps the process defensible.

Common mistakes

The most frequent error is pitching RFI questions at RFP depth. Questions like "provide a full bill of materials and proposed implementation timeline for a 90-unit deployment" are RFP questions. When vendors see them in an RFI, they either decline to respond — the workload isn't justified at an exploratory stage — or they submit a de facto proposal before you've finished defining requirements, locking the conversation prematurely. Keep RFI questions at the market-characterization level: capabilities, regulatory standing, general service architecture (S5).

A closely related mistake is allowing free-form responses. If you don't specify format, you will receive a 40-page product brochure from one vendor, a three-slide PDF from another, and a narrative white paper from a third — none keyed to the same questions. Specifying a maximum of 10–15 pages, requiring section-by-section responses that mirror your question structure, and asking for a single file format dramatically reduces the time your evaluation team spends reformatting rather than assessing (S3).

A third mistake is treating the RFI as a formality with a predetermined outcome. Some procurement teams send the document, collect responses, file them, and then write the RFP based on exactly what they planned to ask anyway. If the RFI findings don't change at least some of your intended RFP specifications, the RFI added process without value. Build in a structured debrief — biomed engineers, clinical stakeholders, and supply chain together — to explicitly identify what the responses revealed that wasn't assumed going in.

Finally, not telling vendors what happens next damages your reputation in the market. Vendors are investing real time in your RFI. State clearly in the document itself that responses will inform an RFP scheduled for a specific approximate date, and that not all RFI respondents will receive the RFP. Transparency here costs nothing and preserves goodwill for future competitive cycles (S1).

A practical workflow

1. List your information gaps before writing a question. Identify what your biomed and clinical teams genuinely don't know about the market — pricing models, integration standards, regulatory landscape — and scope questions only to fill those gaps.
2. Build your vendor long-list from at least three independent sources. Cross-reference your GPO directory, the FDA 510(k) registration database, and ECRI Institute product classifications to reach 8–15 candidates without relying on a single channel.
3. Issue with a formal Q&A window at the midpoint. Publish all questions and answers to every respondent simultaneously, and retain the record as part of your procurement file.
4. Agree on your evaluation criteria before responses arrive. Weight factors such as regulatory compliance, service infrastructure, integration capability, and financial stability in advance so scoring isn't reverse-engineered from the most impressive reply.
5. Hold a structured debrief after scoring. Document specifically which RFI findings will alter your planned RFP specifications; if nothing changes, revisit whether the questions were asked at the right level of depth.
6. Issue the RFP only to vendors who cleared the RFI threshold. Sending the R